We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisers Urge Against Cancer Combo Product Over Safety Concerns
FDA Advisers Urge Against Cancer Combo Product Over Safety Concerns
May 3, 2013
The FDA’s Oncologic Drugs Advisory Committee Thursday voted 16-0 to reject a drug-device combination product for treating a deadly form of liver cancer, citing concerns with safety and lack of supporting data.